Restaging transurethral resection in ta high-grade nonmuscle invasive bladder cancer: a systematic review.
Journal
Current opinion in urology
ISSN: 1473-6586
Titre abrégé: Curr Opin Urol
Pays: United States
ID NLM: 9200621
Informations de publication
Date de publication:
01 Jan 2022
01 Jan 2022
Historique:
pubmed:
24
11
2021
medline:
30
4
2022
entrez:
23
11
2021
Statut:
ppublish
Résumé
The role of a re-transurethral resection (TUR) is clearly demonstrated in T1 high-grade nonmuscle invasive bladder cancer. However, its role remains controversial for Ta high-risk tumors and the recent European guidelines stated that the second look procedure could be avoided for these patients despite harboring a high-risk of both disease recurrence and progression. We aimed to evaluate the added benefit on staging, response to bacillus Calmette-Guérin and oncological outcomes of re-TUR in patients with Ta high-grade nonmuscle invasive bladder cancer. Overall, we identified 15 studies, including 3912 patients from which 743 harbored Ta high-grade disease. Delay between first and second TUR was ranging from 2 to 12 weeks (median 5.6 weeks). The rate of residual disease was 52.8% (range 17-67%). The rate of overall upstaging to T1 and muscle-invasive disease were 10.9 and 4.7%, respectively. Although there was a trend toward improvement of recurrence-free survival outcomes, no definitive conclusions can be drawn due to the retrospective design of the studies included. Residual tumor is common after initial TUR for Ta high-grade. Re-TUR is useful in reducing the rates of residual disease, may improve staging, response to bacillus Calmette-Guérin and oncological outcomes.
Identifiants
pubmed: 34812200
doi: 10.1097/MOU.0000000000000949
pii: 00042307-202201000-00009
doi:
Substances chimiques
BCG Vaccine
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
54-60Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Divrik RT, Şahin AF, Yildirim Ü, et al. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol 2010; 58:185–190.
Cumberbatch MGK, Foerster B, Catto JWF, et al. Repeat transurethral resection in non–muscle-invasive bladder cancer: a systematic review. Eur Urol 2018; 73:925–933.
Herr HW. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus calmette-guerin therapy. J Urol 2005; 174:2134–2137.
Vasdev N, McKie C, Dominguez-Escrig JL, et al. The role of early re-resection in pTaG3 transitional cell carcinoma of the urinary bladder. Br J Med Surg Urol 2011; 4:158–165.
Gordon PC, Thomas F, Noon AP, et al. Long-term outcomes from re-resection for high-risk non–muscle-invasive bladder cancer: a potential to rationalize use. Eur Urol Focus 2019; 5:650–657.
Burger M, Catto JWF, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013; 63:234–241.
Brausi M, Collette L, Kurth K, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002; 41:523–531.
Sylvester RJ, van der Meijden APM, Lamm DL. Intravesical bacillus Calmette–Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168:1964–1970.
Lebret T, Bohin D, Kassardjian Z, et al. Recurrence, progression and success in stage ta grade 3 bladder tumors treated with low dose bacillus calmette-guerin instillations. J Urol 2000; 163:63–67.
Dobruch J, Borówka A, Herr HW. Clinical value of transurethral second resection of bladder tumor: systematic review. Urology 2014; 84:881–885.
Naselli A, Hurle R, Paparella S, et al. Role of restaging transurethral resection for T1 nonmuscle invasive bladder cancer: a systematic review and meta-analysis. Eur Urol Focus 2018; 4:558–567.
Grimm M-O, Steinhoff C, Simon X, et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003; 170:433–437.
Bostwick DG. Natural history of early bladder cancer. J Cell Biochem 1992; 50:31–38.
Herr HW, Donat SM. Quality control in transurethral resection of bladder tumours. BJU Int 2008; 102:1242–1246.
Mariappan P, Zachou A, Grigor KM. Edinburgh Uro-Oncology Group. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol 2010; 57:843–849.
Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in nonrandomised studies of interventions. BMJ 2016; 355:i4919.
Fujikawa A, Iwasaki A, Yumura Y, et al. An evaluation to define the role of repeat transurethral resection in a treatment algorithm for nonmuscle-invasive bladder cancer. Indian J Urol 2012; 28:267.
Han KS, Joung JY, Cho KS, et al. Results of repeated transurethral resection for a second opinion in patients referred for nonmuscle invasive bladder cancer: the referral cancer center experience and review of the literature. J Endourol 2008; 22:2699–704.
Schips L, Augustin H, Zigeuner RE, et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 2002; 59:220–223.
Ali MH, Ismail IY, Eltobgy A, Gobeish A. Evaluation of second-look transurethral resection in restaging of patients with nonmuscle-invasive bladder cancer. J Endourol 2010; 24:2047–2050.
Zurkirchen MA, Sulser T, Gaspert A, Hauri D. Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must even for experienced urologists. Urol Int 2004; 72:99–102.
Geavlete P, Jora T, Georgescu D, Gheorghe N. Value of a second TUR in bladder tumours evaluation and treatment. Eur Urol Suppl 2002; 1:120.
Gendy R, Delprado W, Brenner P, et al. Repeat transurethral resection for nonmuscle-invasive bladder cancer: a contemporary series. BJU Int 2016; 117:54–59.
Ün S, Türk H, Karabiçak M, et al. Is a second look necessary in multiple and/or large Ta tumors? Arch Ital Urol E Androl 2016; 88:86.
Cao M, Yang G, Pan J, et al. Repeated transurethral resection for nonmuscle invasive bladder cancer. Int J Clin Exp Med 2015; 8:1416–1419.
Gill TS, Das RK, Basu S, et al. Predictive factors for residual tumor and tumor upstaging on relook transurethral resection of bladder tumor in nonmuscle invasive bladder cancer. Urol Ann 2014; 6:305–308.
Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49:466-5discussion 475-477.
Gontero P, Sylvester R, Pisano F, et al. The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette–Guérin. BJU Int 2016; 118:44–52.
Knoll T, Omar MI, Maclennan S, et al. Key steps in conducting systematic reviews for underpinning clinical practice guidelines: methodology of the european association of urology. Eur Urol 2018; 73:290–300.